User profiles for N Dand

Nick Dand

- Verified email at kcl.ac.uk - Cited by 2258

Dr. Neha Dand

- Verified email at bvcop.in - Cited by 659

BCS class IV drugs: Highly notorious candidates for formulation development

R Ghadi, N Dand - Journal of Controlled Release, 2017 - Elsevier
… In this study, nicotinamide derivatives, ie N, N-diethylnicotinamide and N-picolylnicotinamide
(DENA) were shown to be powerful hydrotropes for PTX. Copolymers with a segment …

[PDF][PDF] Psoriasis and genetics

N Dand, SK Mahil, F Capon, CH Smith… - Acta Derm …, 2020 - core.ac.uk
Theme issue: Psoriasis loci. Despite the complex correlation structure across the MHC due
to extensive linkage disequilibrium (Box 1)(16), HLA-C* 06: 02 is now confidently considered …

Biomarkers of disease progression in people with psoriasis: a scoping review

…, ML Acencio, IA Barbosa, N Dand… - British Journal of …, 2022 - academic.oup.com
Background Identification of those at risk of more severe psoriasis and/or associated
morbidities offers opportunity for early intervention, reduced disease burden and more cost‐…

[HTML][HTML] Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants

…, E Ellinghaus, JN Barker, V Chandran, N Dand… - Nature …, 2017 - nature.com
Psoriasis is a complex disease of skin with a prevalence of about 2%. We conducted the
largest meta-analysis of genome-wide association studies (GWAS) for psoriasis to date, …

Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID …

Z Izadi, EJ Brenner, SK Mahil, N Dand… - JAMA network …, 2021 - jamanetwork.com
Importance Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally
because of their ability to ameliorate shared immune pathways across immune-mediated …

Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

SK Mahil, N Dand, KJ Mason, ZZN Yiu, T Tsakok… - Journal of allergy and …, 2021 - Elsevier
… have been published elsewhere (n =29 17 and n = 9 18 ). … steroids (n =229), small-molecule
inhibitor (n = 39), or both (n = … (n = 5), multiple conventional systemics or steroids (n = 10), or …

[HTML][HTML] Clinical and genetic differences between pustular psoriasis subtypes

S Twelves, A Mostafa, N Dand, E Burri, K Farkas… - Journal of allergy and …, 2019 - Elsevier
Background The term pustular psoriasis indicates a group of severe skin disorders
characterized by eruptions of neutrophil-filled pustules. The disease, which often manifests with …

HLA-C* 06: 02 genotype is a predictive biomarker of biologic treatment response in psoriasis

N Dand, M Duckworth, D Baudry, A Russell… - Journal of Allergy and …, 2019 - Elsevier
Background Biologic therapies can be highly effective for the treatment of severe psoriasis,
but response for individual patients can vary according to drug. Predictive biomarkers to …

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists …

SK Mahil, N Wilson, N Dand… - British Journal of …, 2020 - academic.oup.com
Background The ‘treat to target’ paradigm improves outcomes and reduces costs in chronic
disease management but is not yet established in psoriasis. Objectives To identify treatment …

An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target

SK Mahil, M Catapano, P Di Meglio, N Dand… - Science translational …, 2017 - science.org
Interleukin (IL)–36α, IL-36β, and IL-36γ are innate mediators of acute epithelial inflammation.
We sought to demonstrate that these cytokines are also required for the pathogenesis of …